iTeos Therapeutics operates as a clinical-stage biopharmaceutical company. The Company discovers and develops immuno-oncology therapeutics for treatment of patients. iTeos Therapeutics serves customers in the United States and Belgium.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
iTeos Therapeutics news
13.05.2022
iTeos Therapeutics' GAAP net income for 3 months of 2022 was $69.582 million, compared to a loss of $13.534 million in the previous year. Revenues were $152.522 million. The company did not generate revenues a year earlier.
Source: 
investors.iteostherapeutics.com
investors.iteostherapeutics.com
24.03.2022
iTeos Therapeutics' GAAP net income for 2021 was $214.521 million, compared to a loss of $38.033 million in the previous year. Revenue was $344.775 million. The company did not generate revenue a year earlier.
Source: investors.iteostherapeutics.com
investors.iteostherapeutics.com
11.11.2021
iTeos Therapeutics' GAAP net income for 9M 2021 was $29.649 million, compared to a loss of $23.129 million in the previous year. Revenues were $104.271 million. The company did not generate revenues a year earlier.
Source: investors.iteostherapeutics.com
investors.iteostherapeutics.com
12.08.2021
iTeos Therapeutics' GAAP loss for 6M 2021 was $39.993 million, up 3.2 times from $12.449 million in the previous year.
Source: investors.iteostherapeutics.com
investors.iteostherapeutics.com
General information
| Company name | iTeos Therapeutics |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 139 MAIN STREET CAMBRIDGE MA 02142 857-204-4583 |
| Mailing address | 139 MAIN STREET CAMBRIDGE MA 02142 |
| Website | investors.iteostherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 